Day One Biopharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Day One Biopharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||
| current assets: | |||||||||||||||||
| cash and cash equivalents | 35,622,000 | 33,358,000 | 124,968,000 | 422,765,000 | 239,616,000 | 270,391,000 | 230,784,000 | 241,179,000 | 189,211,000 | 49,268,000 | 85,262,000 | 120,864,000 | 388,877,000 | 262,731,000 | 284,309,000 | 297,160,000 | 309,996,000 |
| short-term investments | 417,481,000 | 439,662,000 | 406,752,000 | 135,618,000 | 122,250,000 | 47,553,000 | 135,563,000 | 164,359,000 | 253,671,000 | 268,911,000 | 257,007,000 | 253,477,000 | 5,987,000 | ||||
| accounts receivable | 19,669,000 | 18,054,000 | 13,876,000 | 8,695,000 | 9,136,000 | ||||||||||||
| inventory | 6,543,000 | 3,565,000 | 3,321,000 | 2,735,000 | 151,000 | ||||||||||||
| prepaid expenses and other current assets | 15,113,000 | 14,012,000 | 13,413,000 | 11,183,000 | 12,005,000 | 8,090,000 | 8,927,000 | 7,753,000 | 6,902,000 | 4,209,000 | 5,605,000 | 6,172,000 | 7,639,000 | 4,637,000 | 5,059,000 | 6,151,000 | 6,029,000 |
| total current assets | 494,428,000 | 508,651,000 | 562,330,000 | 580,996,000 | 383,158,000 | 326,034,000 | 375,274,000 | 413,291,000 | 449,784,000 | 322,388,000 | 347,874,000 | 380,513,000 | 402,503,000 | 267,368,000 | 289,368,000 | 303,311,000 | 316,025,000 |
| property and equipment | 2,317,000 | 2,508,000 | 2,285,000 | 904,000 | 196,000 | 185,000 | 208,000 | 213,000 | 183,000 | 72,000 | 20,000 | 35,000 | 67,000 | 66,000 | 57,000 | 62,000 | 67,000 |
| operating lease right-of-use asset | 2,499,000 | 2,577,000 | 2,422,000 | 2,574,000 | 164,000 | 259,000 | 352,000 | 442,000 | 530,000 | 616,000 | 699,000 | 864,000 | 993,000 | 180,000 | 227,000 | 273,000 | 319,000 |
| intangible assets | 19,610,000 | 20,405,000 | 15,630,000 | 16,216,000 | 16,802,000 | ||||||||||||
| deposits and other long-term assets | 183,000 | 215,000 | 121,000 | 117,000 | 117,000 | 167,000 | 214,000 | 233,000 | 259,000 | 487,000 | 469,000 | 449,000 | 484,000 | 165,000 | 169,000 | 137,000 | 126,000 |
| total assets | 519,037,000 | 534,356,000 | 582,788,000 | 600,807,000 | 400,437,000 | 326,645,000 | 376,048,000 | 414,179,000 | 450,756,000 | 323,563,000 | 349,062,000 | 381,861,000 | 404,047,000 | 267,779,000 | 289,821,000 | 303,783,000 | 316,537,000 |
| liabilities and stockholders’ equity | |||||||||||||||||
| current liabilities: | |||||||||||||||||
| accounts payable | 5,090,000 | 2,540,000 | 3,262,000 | 3,017,000 | 6,444,000 | 4,780,000 | 2,576,000 | 3,391,000 | 4,565,000 | 4,657,000 | 260,000 | 3,973,000 | 439,000 | 701,000 | 1,744,000 | 683,000 | 348,000 |
| accrued expenses and other current liabilities | 44,131,000 | 43,641,000 | 68,625,000 | 35,189,000 | 87,072,000 | 24,759,000 | 26,524,000 | 20,647,000 | 19,519,000 | 17,774,000 | 15,950,000 | 13,836,000 | 11,933,000 | 7,304,000 | 6,709,000 | 5,161,000 | 4,113,000 |
| current portion of deferred revenue | 1,847,000 | 1,636,000 | 1,554,000 | 1,462,000 | |||||||||||||
| current portion of operating lease liabilities | 153,000 | 62,000 | 10,000 | 77,000 | 300,000 | 408,000 | 437,000 | 428,000 | 417,000 | 405,000 | 462,000 | 427,000 | 171,000 | 204,000 | 202,000 | 201,000 | |
| total current liabilities | 51,221,000 | 47,879,000 | 73,451,000 | 39,745,000 | 93,706,000 | 29,839,000 | 29,508,000 | 24,475,000 | 24,512,000 | 22,848,000 | 16,615,000 | 18,271,000 | 12,799,000 | 8,176,000 | 8,657,000 | 6,046,000 | 4,662,000 |
| long-term portion of deferred revenue | 3,371,000 | 3,350,000 | 3,233,000 | 3,061,000 | |||||||||||||
| long-term portion of operating lease liabilities | 2,850,000 | 2,854,000 | 2,592,000 | 2,538,000 | |||||||||||||
| other long-term liability | 761,000 | 761,000 | 761,000 | ||||||||||||||
| total liabilities | 58,203,000 | 54,844,000 | 80,037,000 | 45,344,000 | 93,706,000 | 29,839,000 | 29,508,000 | 24,552,000 | 24,702,000 | 23,148,000 | 17,023,000 | 18,785,000 | 13,416,000 | 8,176,000 | 8,673,000 | 6,111,000 | 4,774,000 |
| commitments and contingencies | |||||||||||||||||
| stockholders’ equity: | |||||||||||||||||
| common stock | 10,000 | 10,000 | 10,000 | 10,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 7,000 | 7,000 | 7,000 | 7,000 | 6,000 | 6,000 | 6,000 | 6,000 |
| additional paid-in-capital | 1,081,315,000 | 1,069,631,000 | 1,056,738,000 | 1,043,826,000 | 832,148,000 | 817,799,000 | 805,107,000 | 793,699,000 | 783,978,000 | 612,402,000 | 601,771,000 | 593,020,000 | 582,391,000 | 414,831,000 | 408,629,000 | 403,214,000 | 398,065,000 |
| accumulated other comprehensive income | -92,000 | -52,000 | 84,000 | -6,000 | -22,000 | -5,000 | 67,000 | ||||||||||
| accumulated deficit | -620,399,000 | -590,077,000 | -554,081,000 | -488,367,000 | -525,404,000 | -520,997,000 | -458,585,000 | -404,074,000 | -357,924,000 | -312,061,000 | -269,668,000 | -229,559,000 | -191,764,000 | -155,234,000 | -127,487,000 | -105,548,000 | -86,308,000 |
| total stockholders’ equity | 460,834,000 | 479,512,000 | 502,751,000 | 555,463,000 | 306,731,000 | 296,806,000 | 346,540,000 | 389,627,000 | 426,054,000 | 300,415,000 | 332,039,000 | 363,076,000 | 390,631,000 | 259,603,000 | |||
| total liabilities and stockholders' equity | 519,037,000 | 534,356,000 | 582,788,000 | 600,807,000 | 400,437,000 | 326,645,000 | 376,048,000 | 414,179,000 | 450,756,000 | 323,563,000 | 349,062,000 | 381,861,000 | 404,047,000 | 267,779,000 | |||
| current portion of operating lease liability | 190,000 | ||||||||||||||||
| long-term portion of lease liabilities | 77,000 | 190,000 | 300,000 | 408,000 | 514,000 | 617,000 | |||||||||||
| accumulated other comprehensive gain | 9,000 | ||||||||||||||||
| accumulated other comprehensive loss | -7,000 | -9,000 | -71,000 | -392,000 | -3,000 | ||||||||||||
| stockholders’ equity | |||||||||||||||||
| operating lease liabilities, long-term | 16,000 | 65,000 | 112,000 | ||||||||||||||
| liabilities, redeemable convertible preferred shares, redeemable convertible noncontrolling interest and stockholders’ equity/members’ | |||||||||||||||||
| redeemable convertible preferred shares, no par value; no shares authorized, issued and outstanding at december 31, 2021; 22,851,257 shares authorized, issued and outstanding at december 31, 2020 | |||||||||||||||||
| redeemable convertible noncontrolling interest | |||||||||||||||||
| stockholders’ equity/members’ | |||||||||||||||||
| preferred stock, 10,000,000 shares authorized, 0.0001 par value, no shares issued and outstanding at december 31, 2021; no shares authorized, issued, and outstanding at december 31, 2020 | |||||||||||||||||
| common shares, no par value; no shares authorized, issued and outstanding at december 31, 2021; 28,887,127 shares authorized and 6,035,869 shares at december 31, 2020 | |||||||||||||||||
| incentive shares, no par value; no shares authorized, issued and outstanding at december 31, 2021; 4,312,540 shares authorized and 4,112,017 shares issued and outstanding at december 31, 2020 | |||||||||||||||||
| total stockholders’ equity/members’ | 281,148,000 | 297,672,000 | 311,763,000 | ||||||||||||||
| total liabilities, redeemable convertible preferred shares, redeemable convertible noncontrolling interest and members’ deficit | 289,821,000 | 316,537,000 | |||||||||||||||
| redeemable convertible preferred shares, no par value; no shares authorized, issued and outstanding at september 30, 2021; 22,851,257 shares authorized, issued and outstanding at december 31, 2020 | |||||||||||||||||
| preferred stock, 10,000,000 shares authorized, 0.0001 par value, no shares issued and outstanding at september 30, 2021; no shares authorized, issued, and outstanding at december 31, 2020 | |||||||||||||||||
| common shares, no par value; no shares authorized, issued and outstanding at september 30, 2021; 28,887,127 shares authorized and 6,035,869 shares at december 31st, 2020 | |||||||||||||||||
| incentive shares, no par value; no shares authorized, issued and outstanding at september 30, 2021; 4,312,540 shares authorized and 4,112,012 shares issued and outstanding at december 31, 2020 | |||||||||||||||||
| total liabilities, redeemable convertible preferred shares, redeemable convertible noncontrolling interest and stockholders' equity/members' | 303,783,000 | ||||||||||||||||
| redeemable convertible preferred shares, no par value; no shares authorized, issued and outstanding at june 30, 2021; 22,851,257 shares authorized, issued and outstanding at december 31, 2020 | |||||||||||||||||
| preferred stock, 10,000,000 shares authorized, 0.0001 par value, no shares issued and outstanding at june 30, 2021; no shares authorized, issued, and outstanding at december 31, 2020 | |||||||||||||||||
| common shares, no par value; no shares authorized, issued and outstanding at june 30, 2021; 28,887,127 shares authorized and 6,035,869 shares at december 31st, 2020 | |||||||||||||||||
| incentive shares, no par value; no shares authorized, issued and outstanding at june 30, 2021; 4,312,540 shares authorized and 4,112,012 shares issued and outstanding at december 31, 2020 |
We provide you with 20 years of balance sheets for Day One Biopharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Day One Biopharmaceuticals. Explore the full financial landscape of Day One Biopharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Day One Biopharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.